Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells
- 28 January 1994
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 263 (5146) , 518-520
- https://doi.org/10.1126/science.7507262
Abstract
Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4 + and CD8 + cells were essential for the induction of protective immunity; however, only CD8 + cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.Keywords
This publication has 12 references indexed in Scilit:
- Identification of human cancers deficient in antigen processing.The Journal of Experimental Medicine, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNAScience, 1993
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 1992
- CTLA-4 is a second receptor for the B cell activation antigen B7.The Journal of Experimental Medicine, 1991
- Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.The Journal of Experimental Medicine, 1991
- Problems in the investigational study and clinical use of cancer immunotherapyImmunology Today, 1990
- Receptor-Mediated Antigen Uptake and its Effect on Antigen Presentation to Class II-Restricted T LymphocytesAnnual Review of Immunology, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989